Publications
2024
The Role of NRAS in Acute Myeloid Leukaemia
Healy, F. (2024, March 8). The Role of NRAS in Acute Myeloid Leukaemia.
Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?
Healy, F. M., Turner, A. L., Marensi, V., & MacEwan, D. J. (n.d.). Mediating kinase activity in Ras-mutant cancer: potential for an individualised approach?. Frontiers in Pharmacology, 15. doi:10.3389/fphar.2024.1441938
2023
NRAS contributes to drug-resistant acute myeloid leukaemia
Healy, F. M., Marensi, V., Woolley, J. F., & MacEwan, D. J. (2023). NRAS contributes to drug-resistant acute myeloid leukaemia. In BRITISH JOURNAL OF PHARMACOLOGY Vol. 180 (pp. 492). Retrieved from https://www.webofscience.com/
2022
P408: NRAS MUTATIONS ARE INVOLVED IN ACUTE MYELOID LEUKAEMIA DRUG RESISTANCE
Healy, F., Marensi, V., Woolley, J., & MacEwan, D. (n.d.). P408: NRAS MUTATIONS ARE INVOLVED IN ACUTE MYELOID LEUKAEMIA DRUG RESISTANCE. HemaSphere, 6, 308-309. doi:10.1097/01.hs9.0000844520.69163.7a
The importance of Ras in drug resistance in cancer
Healy, F. M., Prior, I. A., & MacEwan, D. J. (2022). The importance of Ras in drug resistance in cancer. BRITISH JOURNAL OF PHARMACOLOGY, 179(12), 2844-2867. doi:10.1111/bph.15420
Worked to the bone: antibody-based conditioning as the future of transplant biology
Griffin, J. M., Healy, F. M., Dahal, L. N., Floisand, Y., & Woolley, J. F. (2022). Worked to the bone: antibody-based conditioning as the future of transplant biology. JOURNAL OF HEMATOLOGY & ONCOLOGY, 15(1). doi:10.1186/s13045-022-01284-6
2021
Recent Progress in Interferon Therapy for Myeloid Malignancies
Healy, F. M., Dahal, L. N., Jones, J. R. E., Floisand, Y., & Woolley, J. F. (2021). Recent Progress in Interferon Therapy for Myeloid Malignancies. FRONTIERS IN ONCOLOGY, 11. doi:10.3389/fonc.2021.769628
NRAS mutations arise in resistance to FLT3 inhibitors in acute myeloid leukaemia
Healy, F., Marensi, V., Maerken, M., Anyfantis, G., Woolley, J., & MacEwan, D. (2021). NRAS mutations arise in resistance to FLT3 inhibitors in acute myeloid leukaemia. In BRITISH JOURNAL OF PHARMACOLOGY Vol. 178 (pp. 4949-4950). Retrieved from https://www.webofscience.com/